SDGR
Schrodinger Inc

6,244
Loading...
Loading...
News
all
press releases
Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 40.4% in Schrodinger (SDGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·10d ago
News Placeholder
More News
News Placeholder
Schrodinger Downgraded By Citi After Ending Blood Cancer Drug Trial Tied To 2 Deaths; Retail Voices Concern
Shares closed at a four-month low before edging slightly higher after hours as investors digested the pipeline setback and cautious outlook.
Stocktwits·1mo ago
News Placeholder
Schrödinger Discontinues Clinical Program After Two Patient Deaths
SGR-2921 was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Stocktwits·1mo ago
News Placeholder
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates
Schrodinger (SDGR) delivered earnings and revenue surprises of +28.92% and +5.08%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Clover Health Investments, Corp. (CLOV) Q2 Earnings Meet Estimates
Clover Health Investments (CLOV) delivered earnings and revenue surprises of 0.00% and -1.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition?
VEEV leans on Vault R&D for growth as AI-native rivals rise, testing its edge in clinical and regulatory innovation.
Zacks·2mo ago
News Placeholder
Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
Zacks·2mo ago
News Placeholder
Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Schrodinger (SDGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
Zacks·2mo ago

Latest SDGR News

View

Advertisement. Remove ads.

Advertisement. Remove ads.